Back to Search
Start Over
Effect of everolimus treatment for regrown renal angiomyolipoma associated with tuberous sclerosis complex after transcatheter arterial embolization.
- Source :
-
International Journal of Clinical Oncology . Dec2018, Vol. 23 Issue 6, p1134-1139. 6p. - Publication Year :
- 2018
-
Abstract
- Background: The aim of this study was to evaluate the effects and the utility of second-line everolimus treatment for regrown renal angiomyolipoma (AML) with tuberous sclerosis complex (TSC) after transcatheter arterial embolization (TAE).Methods: We investigated a total of 14 patients who underwent second-line everolimus treatment for TSC-AML that regrew after TAE, and assessed their effects and adverse events. Everolimus treatment was performed for AML with a maximum diameter of 4 cm. To determine the reduction ratio of AML, the volume of AML was measured using multislice helical computed tomography. Adverse events were evaluated according to CTCAE v4.0-JCOG. We further compared the treatment effect and adverse events with those in patients receiving first-line everolimus treatment.Results: The AML volume decreased in all patients, with a ≥ 50% volume decrease in 57% (8 of 14) of the cases, and the mean reduction rate was 53%. We observed no significant difference in the mean reduction rate of AML between second-line everolimus treatment for regrown TSC-AML after TAE and first-line everolimus treatment for TSC-AML. The adverse events were mild and consistent with those reported in our previous study.Conclusion: Although further studies are needed, everolimus appears to be effective as second-line treatment for TSC-AML that regrew after TAE and a beneficial treatment option for TSC-AML. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 13419625
- Volume :
- 23
- Issue :
- 6
- Database :
- Academic Search Index
- Journal :
- International Journal of Clinical Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 133160618
- Full Text :
- https://doi.org/10.1007/s10147-018-1325-0